Für Forschende
I. Echeverria , A. Besga, B. Sanz, et al.Eur J Clin Invest . 2020 Oct 5;e13420. doi: 10.1111/eci.13420. People with frailty and/or sarcopenia have an increased risk of negative health outcomes. However, their diagnosis is often difficult. Considering the potential value of myostatin and follistatin as biomarkers of these conditions, we aimed to compare the association between both myokines and frailty and/or sarcopenia in post-hospitalised older people. In addition, the capability of myostatin and follistatin for identifying frailty and sarcopenia was compared with physical tests. |
D. Montiel-Rojas, A. Nilsson, A. Santoro, et al.Nutrients. 2020 Apr; 12(4): 1075. doi: 10.3390/nu12041075. Sarcopenia is characterised by a progressive loss of skeletal muscle mass and physical function as well as related metabolic disturbances. While fibre-rich diets can influence metabolic health outcomes, the impact on skeletal muscle mass and function is yet to be determined, and the moderating effects by physical activity (PA) need to be considered. |
S.P. Rajan, M. Anwar, B. Jain, et al.Aging Clin Exp Res. 2020 Jun 27. doi: 10.1007/s40520-020-01642-9. The study aims to identify sarcopenia in older adults using Asian Working group guidelines (AWGS) to determine clinically relevant cut-off levels for diagnosis and their association with antioxidant protein Sesns. |
H.J. Coelho-Junior, R. Calvani, A. Picca, et al.Nutrients. 2020 Jun 1;12(6):E1635. doi: 10.3390/nu12061635. The present study investigated and compared the patterns of dietary protein intake and physical function in Brazilian and Italian older women. |
S. Mankhong, S. Kim, S. Moon, et al.Cells . 2020 Jun 2;9(6):E1385. doi: 10.3390/cells9061385. In this article we describe the fundamental aging mechanisms. Next, e discuss both in vitro and in vivo experimental models based on molecular mechanisms that have the potential to elucidate the biochemical processes integral to sarcopenia. Lastly, we discuss the possible molecular targets and the current status of drug candidates for sarcopenia treatment. |
E. Gielen, D. Beckwée, A. Delaere, et al.Nutr Rev. 2020;nuaa011. doi:10.1093/nutrit/nuaa011. The aim of this umbrella review was to provide an evidence-based overview of nutritional interventions targeting sarcopenia or at least 1 of the 3 sarcopenia criteria (ie, muscle mass, muscle strength, or physical performance) in persons aged ≥ 65 years. |